Solid pseudopapillary neoplasm (SPN) is an extremely rare pancreatic epithelial neoplasm with low malignancy that affects mainly young females. It is characterized by a good prognosis, even in the presence of metastases. SPNs have a particular avidity for Given the particular avidity for 18 F-FDG, SPNs can be easily recognized on 18 F-FDG PET/CT. However, this exam is not useful in differentiating this neoplasm from other malignant pancreatic solid lesions, but it could give a contribution to the staging by the ability to identify potential metastases or recurrences.
Introduction
Solid pseudopapillary neoplasm (SPN) of the pancreas is an extremely rare epithelial tumor (1, 2) . The first cases of SPN were described by Frantz in 1959. Since then, these lesions have been identified with different names until 2010 when the World Health Organization (WHO) defined SPN as a "low malignant epithelial neoplasm" and eliminated the term tumor (1) (2) (3) .
Since the first description, a lot has been understood about the clinic, diagnosis, therapy and prognosis of this neoplasm; nevertheless, the etiology has still not been fully understood (1) . SPNs are very rare pancreatic tumors, accounting for approximately 0.2% -2.7% of all exocrine pancreatic tumors, although with recent improvements in imaging the incidence increased up to 5% -6% of all pancreatic tumors diagnosed, mainly affecting females (femalemale ratio of 8:1) and young patients (between 28.5 and 36.8 years) (1, 2) . SPNs have a good prognosis, even in the presence of distant metastases (1, 2) .
Endoscopic ultrasound (EUS), computed tomography (CT) and magnetic resonance imaging (MRI), have increased the diagnosis of these lesions, often identified as incidentalomas (1, 4, 5) . However, in order to make a better characterization of the primary lesion, staging and differential diagnosis with other and more fearsome pancreatic lesions (ductal adenocarcinoma, neuroendocrine tumor), to better determine the best treatment strategy, 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) can be of great help to the clinician based on a particular avidity of SPNs for 18 F-FDG (6-9). Nonetheless, there are very few papers in the literature on the use of 18 F-FDG PET/CT in the diagnosis and staging of SPNs (6) . We present the case of a young woman who presented to our attention with gastric outlet obstruction caused by a massive pancreatic SPN whose pre-operative staging was achieved thanks to the contribution of 18 F-FDG PET/CT.
Case Presentation
We present the case of a 23-year-old Caribbean woman who arrived in the emergency department complaining of abdominal discomfort, nausea, difficult digestion, and recurrent vomiting for approximately six months. She had a personal history of bariatric surgery (laparoscopic sleeve gastrectomy performed in 2014) after which she had a weight loss of 34 kg. Initially, the current symptoms were considered to be related to the important weight loss and as sequel of the bariatric surgery. The patient denied any drug intake.
On admission, the patient presented with normochromic skin (no jaundice and no anemia), high blood pressure, heart rate in the normal range, and body mass index (BMI) of 20.47. The abdomen was flat without tenderness, pain or signs of peritonism. In palpation, we found the presence of a mass in the epimesogastric regions that seemed fixed to nearby tissues. Her laboratory tests were normal, including tumor and inflammatory markers. Abdomen US showed a capsulated, hypo-isoechoic pancreatic lesion of 98 mm × 67 mm. After All the collected data came out in favor of the diagnosis towards SPN but after multidisciplinary assessment, on the basis of the significant size of the lesion, it was decided to perform a 18 F-FDG PET/CT ( Figure 2 ) in order to identify potential metastases. The exam showed a massive area of pathological fixation of the radiopharmaceutical (SUVmax 10) in correspondence to the pancreatic head lesion described on CT and US. In addition, there was an accumulation of radiopharmaceutical in the stomach related to the scars of previous surgery. However, there was no evidence of further hypercaptations attributable to metastasis.
After complete staging, a pancreaticoduodenectomy was performed (Figure 3 ). Histological examination of the surgical specimen confirmed the diagnosis of SPN ( Figure  4 ). The clinical course was uneventful, and the patient was discharged 24 days after surgery. After 12 months of followup she is in excellent clinical condition with no evidence of recurrence or metastasis.
Discussion
To date, referring to several articles in the current literature about the diagnosis and staging of pancreatic SPNs, we can see how the almost exclusively cited exams are EUS and CT/MRI, while 18 F-FDG PET/CT has only been reported rarely (in 2005, Lee et al. were the first to describe the hyperaccumulation of 18 F-FDG in SPN) (1, (6) (7) (8) (9) .
SPN is generally a benign lesion; however, it almost always shows glucose hypermetabolism on PET scans (whether the lesion is benign or malignant), a feature that distinguishes malignant tumors (9) . As in our case, the massive lesion of the pancreatic head, albeit with benign histological features, showed a hyperaccumulation of radiopharmaceutical (SUVmax 10) in agreement with the results in different case reports/case series (SUVmax range 2.6 to 42.8) (6-11).
As suggested by several authors, this particular avidity for 18 F-FDG of SPN could be dependent on some of its histopathological features, such as a high cellular density, rich mitochondria, and its hypervascular nature (6-10). Dong et al. hypothesized that among SPNs greater hyperaccumulation of 18 F-FDG characterized those with a higher solid component than those with a less solid component, probably for two main reasons, first, the cystic-necrotic component shows low 18 F-FDG uptake and second, the cellular component has a lower density than a lesion with little or no cystic-necrotic component (8) . In full agreement with this hypothesis is our case, in which the lesion showed a low cystic-necrotic component despite the considerable size, and a marked solid cellular component. The molecular mechanisms involved in glucose uptake in SPN are not clearly understood (11) . As reported by Guan et al., glucose transporter-1 (Glut-1) and hexokinase-II (HK-II) play key roles in the uptake and trapping of 18 F-FDG.
However, poor expression of GLUT-1 and moderate expression of HK-II in SPN cells have been reported (9) . Furthermore, from the analysis of their data, they revealed no incidence of gender and age on SUVmax value as well as a poor correlation between SUVmax and the size of the lesion (9 cose metabolic activity, is probably the result of high SPN cellularity, as already advocated by Guan et al. (7, 9) .
PET scan is increasing its acceptance as a valid tool in the differential diagnosis and staging of pancreatic tumors, along with CT and MRI (which have always been the first imaging choices in primary diagnosis). We can find high SUVmax values even in the presence of other histological types of pancreatic solid lesions (1-3) . Indeed, 18 F-FDG PET/CT, in addition to identifying almost all cases of SPN with a SUVmax value > 2.6 is able to detect other pancreatic solid lesions such as pancreatic adenocarcinoma (PAC) and pancreatic neuroendocrine tumor (PNET). However, in some occasions, the latter ones, may present a low SUVmax value that results in a poor 18 F-FDG uptake, as in the case of small size PAC with low cellular density and/or high fibrous content, or as in well-differentiated PNET (9). These two histologic types can show SUVmax values < 2.6 in 14% and 21.4%, respectively (9) . Discriminating between an SPN, a PAC or a PNET is of extreme importance for the clinician and the patient given the good prognosis that SPN could have, after resection of the primary tumor and/or recurrent lesions and/or metastatic lesions in case of malignancy. Nevertheless, we cannot differentiate these pancreatic solid lesions from SPN based only on SUVmax values > 2.6 (9).
Some authors have looked for a possible correlation 
